nemaura medical  nemaura medical nemaura medical   search investors  home technology sugarbeat® about us leadership news contact us better diagnostics for life innovative rdled patented biomedical diagnostic technologies nemaura medical focusses on some of the world’s most pressing health concerns delivering precise direct knowledge of individual’s health and wellbeing at all times our needlefree and patientfriendly technology has the potential to transform health monitoring by providing realtime tailored feedback on glucose lactate and other key body performance metrics our beat™ technology platform convenient timely and painless our needlefree patented beat™ technology is applied to the skin via a small unobtrusive patch show more  show less  transmitting this data to users and  or healthcare professionals via a smartphone app the technology will allow realtime monitoring of medical conditions and chronic diseases for better management or treatment encouraging compliance due to its ease and flexibility of use our technology is expected to provide substantial savings to patients while potentially helping to significantly reduce future health complications for many medical conditions applications key market applications include diabetes a growing concern for healthcare providers and governments across the globe as diabetes cases continue to soar potential critical care applications include lactate monitoring to prevent lactic acidosis a potentially fatal drop in the ph of tissues and blood due to a buildup of lactate after a trauma or depletion of body fluids monitoring lactate via our technology can also offer tangible benefits to the field of endurance and performance training find out more  sugarbeat® suitable for type  and type  diabetics sugarbeat® is a noninvasive affordable glucose monitoring system combining patented patch technology with a small electronic sensor sugarbeat® provides realtime monitoring for better health management find out more  stay informed  commentsthis field is for validation purposes and should be left unchanged get in touch  copyright   nemaura all rights reserved code of business conduct and ethics cookie  privacy policy cookie  privacy policy  nemaura medical nemaura medical   search investors  home technology sugarbeat® about us leadership news contact us privacy policy we believe your right to privacy should be protected at all times we are committed to protecting your privacy and the information we collect is either essential to use our service or for the purpose of enhancing your experience we will never supply this information to anyone without your approval read on if you require more details this policy together with any other documents referred to within sets out the basis on which we will process any personal data that we collect from you or that you provide to us please read the following carefully to understand our views and practices regarding your personal data and how we will treat it for the purpose of the data protection act  act the data controller is nemaura medical inc advanced technology innovation centre oakwood drive loughborough le qf united kingdom  individuals whose data we collect and process visitors to our website at httpwwwnemauramedicalcom ‘site’ who may or may not be registered with us ‘public users’  information we process about individuals we may collect and process the following data about individuals  information that you provide by filling in forms on our site – this includes information provided at the time of contacting us  if you contact us we may keep a record of that correspondence  details of your visits to our site including but not limited to traffic data location data weblogs and other communication data and the resources that you access and  any information incidental to that listed above  ip addresses cookies and similar technologies  we may collect information about your computer including where available your ip address operating system and browser type for system administration purposes this is statistical data about our users’ browsing actions and patterns and does not identify any individual  we may obtain information about your general internet usage by using technology such as “cookies” which store information on the hard drive of your computer this type of technology helps us to improve our site and to deliver a better and more personalised service they enable us  to understand visitor numbers  to store information about a public user’s preferences and so allow us to customise our site according to a public user’s interests and offer them goods or services in which we believe they will be interested  to speed up your searches and  to recognise you when you return to our site  to find out more about cookies including how to control and disable them please visit httpwwwallaboutcookiesorg  you may refuse to accept some technologies such as cookies by activating settings on your browser which allows you to refuse the setting of technologies such as cookies if you refuse all cookies you may be unable to access certain parts of our site if you do not activate these settings on your browser then you will be taken to have consented to the use of these technologies  we use google analytics and other monitoring software on our site these types of technologies also allow the proprietor of the technology eg google to also access your information but where possible or practicable in line with the type of monitoring we have restricted this to anonymous information  where we store an individual’s personal data the data that we collect from you via forms will be stored at a destination inside the european economic area “eea” data collected via google analytics is stored as documented in their terms of service httpswwwgooglecoukanalyticstermsgbhtml by submitting your personal data you agree to this transfer storing or processing we will take all steps reasonably necessary to ensure that your data is treated securely and in accordance with this privacy policy  how we use your information  we use information held about you in the following ways  to ensure that content from our site is presented in the most effective manner for you and for your computer  to provide you with information products or services that you request from us or which we feel may interest you where you have consented to be contacted for such purposes  to carry out our obligations arising from any contracts entered into between you and us  sharing your information  except where it is part of our use of tracking technologies such as google analytics we do not share any information with third parties without your explicit consent  links to other sites our site may from time to time contain links to and from the websites of our partners advertisers and affiliates if you follow a link to any of these websites please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies please check these policies before you submit any personal data to these websites  accessing your information  the act gives you the right to access information held about you you can find out if we hold any personal information about you by making a “subject access request” under the data protection act  if we do hold information about you we will  give you a description of it  tell you why we are holding it  tell you who it could be disclosed to and  let you have a copy  any formal subject access request should be made in writing to the address above and may be subject to a fee of £ to meet our costs in providing you with the details of the information we hold about you  changes to our privacy policy any changes we may make to our privacy policy in the future will be posted on this page and where appropriate notified to you by email  contact questions comments and requests regarding this privacy policy are welcomed and should be addressed to enquiriesnemauracom or in writing nemaura medical inc advanced technology innovation centre oakwood drive loughborough le qf united kingdom  terms of use the following terms of use cover the use of nemaura medical inc’s website and by using this site you accept these terms the copyright in the material contained on this website belongs to nemaura medical inc this copyright includes the content coding graphics and all aspects of this website nemaura medical inc hereby authorises you to copy documents or pages published by us on this web site for your noncommercial use only provided any copy of these documents that you make retain all copyright or other proprietary notices and any disclaimer contained thereon except for this limited permission nothing on this site should be construed as granting any other right or licence under any copyright of nemaura medical inc nemaura medical inc is not responsible for any third party website that may be accessed via links to and from this website we make no representations whatsoever about any other websites which you may access through this one and accept no responsibility for any information contained within such linked websites it is up to you to take precautions to ensure that whatever you select for your use is free of such items as viruses and like devices this website is provided for general informational purposes only nemaura medical inc does not guarantee the accuracy of the information contained within this website and accepts no responsibility for any omissions or errors nemaura medical inc is continually adding to and modifying its range of products and to reflect this our website is updated on an ongoing basis we do not consequently warrant that the information contained within this site will be complete and accurate at all times nemaura medical inc and its related companies exclude all liability for any loss whatsoever or damage arising directly or indirectly out of the use of this website or any content contained herein any dispute arising from the use or content of this website or any related websites shall be subject to the laws of england and wales   nemaura medical inc registered office advanced technology innovation centre oakwood drive loughborough le qf united kingdom t      for general enquiries please email enquiriesnemauracom  copyright  nemaura medical inc all rights reserved stay informed  phonethis field is for validation purposes and should be left unchanged get in touch  copyright   nemaura all rights reserved code of business conduct and ethics cookie  privacy policy investors  nemaura medical nemaura medical   search investors  home technology sugarbeat® about us leadership news contact us leading the way in patientled diagnostics we believe in putting users at the heart of healthcare bringing together the power of revolutionary noninvasive diagnostic devices and the convenience of patientfriendly technology we believe in empowering patients to better manage their own health and wellness potentially enhancing the life they lead both now and in the future empowering patients enhancing healthcare always striving for precise and accurate knowledge of people’s health and wellbeing nemaura medical is a biotech life sciences rd company with proprietary patentprotected technology focussed on diagnostic techniques via the skin its technology has potential applications for a broad range of globallyrelevant medical conditions and wellbeing uses significant opportunities lie in the diabetes athletic performance intensive care and wider diagnostics markets to continue the commercialisation of its technology and diversification into new applications nemaura medical is actively seeking partners licensees and collaborators globally for more information please contact us key facts  headquarters and research facilities in the united kingdom loughborough science park us registered company  proprietary patentprotected technology for monitoring medical conditions via the skin with broad portfolio of patents both pending and granted  first product sugarbeat® has received a ce approval in europe for its first device and has ongoing clinical studies to support product launches in multiple territories  strong pipeline of additional products for key market opportunities company performance latest report download our latest report here download  code of ethics the company also maintains a code of business conduct and ethics that is approved by the board of directors find out more  stay informed  namethis field is for validation purposes and should be left unchanged get in touch  copyright   nemaura all rights reserved code of business conduct and ethics cookie  privacy policy nmrdotc us stock quote  nemaura medical inc  bloomberg markets error could not add to watchlist x  watchlist nemaura medical inc nmrdus otc us usd   as of  pm edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap b usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry health care equipment  services  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later  nemaura appoints dr salim natha to board of directors as independent director chair of compensation committee  nemaura signs letter of intent for licensing agreement with tpm for gcc region  nemaura appoints timothy johnson to board of directors as independent director chairman of audit and corporate governance  nemaura medical inc announces uplist to otcqb  nemaura medical inc reports full year financial results  nemaura medical inc reports major improvement in sugarbeat® sensor performance  nemaura medical inc successfully completes development of secondgeneration sugarbeat® noninvasive continuous glucose  nemaura medical inc to present sugarbeat® poster at the advanced technologies and treatments for diabetes symposium attd in there are currently no press releases for this ticker please check back later profile nemaura medical inc designs and develops proprietary drug delivery platforms the company produces therapeutic delivery systems including patches and injectors nemaura medical offers its products to the pharmaceutical and healthcare industries address charnwood building holywell pashby roadloughborough le aqunited kingdom phone  website wwwnemauramedicalcom executives board members dewan fazlul hoque chowdhury chairmanpresidentceo iain anderson chief financial officer karrar khan directorproduct development david scott directorcommercial development  licensing bashir timol investor relations show more nemaura medical announces joint venture for european launch of sugarbeat® system  business wire nemaura medical announces joint venture for european launch of sugarbeat® system december    am eastern standard time loughborough englandbusiness wirenemaura medical inc otc bb nmrdnemaura a medical device company developing a minimally invasive wireless continuous glucose monitoring “cgm” system known as sugarbeat® announced today that it has entered into an equal joint venture agreement with dbj jersey to market the sugarbeat® system in europe the sugarbeat® cgm system is designed to display real time glucose readings on the device and on a mobile phone app via blue tooth or allow retrospective evaluation of the data for glucose trending nemaura has patents that allow the device to selfcalibrate using an internal standard concept which is expected to eliminate the need for routine daily fingerprick calibrations the company anticipates a launch in europe during  pending obtaining requisite product approvals for which the operational aspects of the launch will be entirely managed by dbj jersey under the terms of the agreement with product support from nemaura medical dbj jersey is headed by its founder dr dallas burston mbbs a pharmaceutical entrepreneur with an outstanding track record having founded and sold companies in this field totaling over usm with the most recent sale led by cavendish corporate finance dr burston stated “the methods of measuring blood glucose levels and managing the longerterm complications of diabetes are expanding very quickly the landscape is rapidly changing towards less invasive wearable devices europe represents a us  billion market opportunity and together with intelligent use of data i believe that there is potential to reduce the overall healthcare burden” in addition dr burston purchased  million shares in nemaura medical for usm and was issued a warrant to acquire an additional ten million shares at an exercise price of  subject to customary antidilution provisions and other conditions on exercise set forth in the warrant agreement dr faz chowdhury ceo of nemaura medical inc stated “nemauras sugarbeat® system has been developed to provide a very cost effective and minimally invasive alternative for diabetics we are very excited to have dbj with its impeccable track record of advancing the adoption of new technologies as our partner in europe once requisite product approvals have been obtained” about nemaura medical inc nemaura medical is developing the sugarbeat® system as a minimallyinvasive wireless continuous glucose monitoring system for use as an adjunct device for blood glucose monitoring further opportunity may exist for use of the device in intensive care hospital settings where continuous glucose monitoring is critical cautionary statement regarding forward looking statements the statements in this press release that are not historical facts and may constitute forwardlooking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements those risks and uncertainties include but are not limited to risks related to regulatory approvals and the success of nemaura’s ongoing studies including the safety and efficacy of nemaura’s sugarbeat® cgm system the failure of future development and preliminary marketing efforts nemaura’s ability to secure additional commercial partnering arrangements risks and uncertainties relating to nemaura and its partners ability to develop market and sell the sugarbeat® system the availability of substantial additional equity or debt capital to support its research development and product commercialization activities and the success of its research development regulatory approval marketing and distribution plans and strategies including those plans and strategies related to its sugarbeat® system these and other risks and uncertainties are identified and described in more detail in nemaura’s filings with the securities and exchange commission including without limitation its annual report on form k for the current year its quarterly reports on form q and its current reports on form k nemaura undertakes no obligation to publicly update or revise any forwardlooking statements wwwnemauramedicalcom contacts investors  medianemaura medical incbashir timolbashirtimolnemauracom   ormbs value partnersbetsy brod release summary nemaura medical announces joint venture for european launch of sugarbeat® system contacts investors  medianemaura medical incbashir timolbashirtimolnemauracom   ormbs value partnersbetsy brod search advanced news search advanced news search log in sign up nmrd key statistics  nemaura medical inc financial ratios  marketwatch bulletin investor alert new york markets open in market snapshot analyst ratings expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close nemaura medical inc otc nmrd go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus nemaura medical inc market closed  quotes are delayed by  min jul    pm nmrd quoteszigmandelayed   change   volume volume  quotes are delayed by  min quoteszigmandelayed previous close     change   day low day high    week low  week high   company description nemaura medical inc is a holding company that provides medical device research and manufacturing through its subsidiaries it specializes in discovering developing and commercializing a continuous glucose monitoring device which consists of a disposable patch containing a sensor and a nondispo nemaura medical inc is a holding company that provides medical device research and manufacturing through its subsidiaries it specializes in discovering developing and commercializing a continuous glucose monitoring device which consists of a disposable patch containing a sensor and a nondisposable miniature electronic watch with a rechargeable power source the company was founded by dewan fazlul hoque chowdhury on december   and is headquartered in loughborough the united kingdom valuation pe current  pe ratio with extraordinary items  price to book ratio  enterprise value to ebitda  efficiency income per employee  liquidity current ratio  quick ratio  cash ratio  profitability return on assets  return on equity  return on total capital  return on invested capital  capital structure officers and executives name age officer since title dr dewan fazlul hoque chowdhury   chairman president  chief executive officer mr iain anderson   chief financial officer dr richard toon   managertechnical  business development mr david scott   directorcommercial development  licensing mr karrar khan   directorproduct development insider actions – purchase – sale  – number of transactions  newslatestcompanyusnmrd marketwatch news on nmrd no news currently available for nmrd newsnonmarketwatchcompanyusnmrd other news on nmrd k nemaura medical inc  pm june    edgar online  edg  q k continuous glucose monitoring systems  a growing market  am dec    seeking alpha q nemaura medical inc  am nov    edgar online  edg  q k q nemaura medical inc  pm aug    edgar online  edg  q k at a glance nemaura medical inc advanced technology innovation ctr lusep  oakwood drive loughborough leicestershire le qf phone  industry medical equipmentsupplies sector health carelife sciences fiscal yearend  view sec filings revenue na net income m employees  annual report for nmrd newspressreleasecompanyusnmrd press releases on nmrd nemaura appoints dr salim natha to board of directors as independent director chair of compensation committee  am july    businesswire  bzx nemaura signs letter of intent for licensing agreement with tpm for gcc region  am july    businesswire  bzx nemaura appoints timothy johnson to board of directors as independent director chairman of audit and corporate governance committees  pm july    businesswire  bzx nemaura medical inc announces uplist to otcqb  am july    businesswire  bzx nemaura medical inc reports full year financial results  am june    businesswire  bzx nemaura medical inc reports major improvement in sugarbeat® sensor performance  pm june    businesswire  bzx global wearable adhesive market   pm april    pr newswire  prf nemaura medical inc successfully completes development of secondgeneration sugarbeat® noninvasive continuous glucose monitoring skinpatch  am april    businesswire  bzx global diabetes diagnostics industry  pm feb    pr newswire  prf nemaura medical inc to present sugarbeat® poster at the advanced technologies and treatments for diabetes symposium attd in paris february th   am feb    businesswire  bzx nemaura medical inc sign letter of intent with shenzen cas health corp for potential jv and manufacture of their sugarbeat® system  am sept    businesswire  bzx nemaura medical inc completes second fda presubmission meeting and appoints navigant to submit ide for nemaura’s sugarbeat® system  am aug    businesswire  bzx trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest ahuawei smartphone shipments jump revenue soars afoxtons profit falls  as brexit hits market ajust eat profit jumps  ups revenue guidance aftse  steady as astrazeneca plunges diageo surges adaily mail revenue up warns on some markets aweir profit jumps on strong oil and gas showing asmith  nephew profit rises on track for targets aspains unemployment rate drops to  avolkswagen profit up lifts sales guidance athomas cook loss halves backs fullyear guidance alloyds profit narrows on £ bln compensation bill aairbus profit down  on lower plane deliveries atate  lyle profit ahead backs fullyear guidance aoil majors sustain profits despite crudes slide aastrazenecas mystic cancer drug trial fails aastrazenecas mystic lung cancer trial fails to meet endpoint aastrazeneca tumbles  after decline in quarterly revenue adeutsche bank shares falls  after earnings report aanglo american up  after dividend reinstatement agermanys dax opens  lower at  loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  nemaura medical inc nmrdpk people  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states nemaura medical inc nmrdpk related topics stocksstock screenermarket datahealthcaremedical equipment supplies  distribution overview news key developments people charts financials analysts research pulse nmrdpk on otc markets group usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  summary name age since current position dewan chowdhury   chairman of the board president chief executive officer iain anderson  chief financial officer karrar khan  director of product development david scott  director of commercial development and licensing richard toon  business and technical development manager bashir timol   director timothy johnson  independent director » insider trading biographies name description dewan chowdhury dr dewan fazlul hoque chowdhury is chairman of the board president chief executive officer of the company since january   he is in charge of research and development of our core technologies product development innovation and commercialization he also coordinates and oversees legal compliance development of the company mission policy and planning prior to establishing the company dr chowdhury was the founder and ceo of microneedle technologies and nemaura pharma limited where he played a pivotal role in the development manufacture and launch of a microneedle device used in skin clinics which is also currently being evaluated for skin cancer drug delivery dr chowdhury has been responsible for negotiating licensing deals for a transdermal patch to treat alzheimers disease additionally he was involved in negotiations for outlicensing patches to treat parkinsons and hypertension and inlicensing complementary technologies dr chowdhury originally trained as a pharmaceutical scientist and has an msc in microsystems and nanotechnology from cranfield university and a doctorate from the university of oxford on nanodrug delivery his experience in the pharmaceutical industry includes product development manufacturing and technical and corporate management iain anderson mr iain anderson serves as chief financial officer of the company mr anderson has served as the financial controller for the company on a parttime basis since august  his responsibilities include the preparation and management of the companys accounts prior to his employment with the company mr anderson had more than  years experience in working for usowned businesses from may  to july  mr anderson was the european controller for lamons a division of trimas corporation from december  to april  he was the financial controller for sps technologies limited a subsidiary of precision castparts corporation from may  to november  he was head of accounting – northern europe for hospira inc from may  to april  he was financial controller for air bearings limited a subsidiary of hitachi mr anderson has been a chartered certified accountant since  mr anderson received a masters in business administration from loughborough university in  karrar khan mr karrar khan is director of product development of the company he received his ba in  and his phd from portsmouth university in  his experience includes  years as head of pharmaceutical development for boots pharmaceuticals and knoll and two years as director for osi where he managed their pharmaceutical development analytical operations and dmpk his expertise ranges from development for phase  to phase   and significant experience of bringing prescription and otc products to market on a global level professor khan is a qualified person under the ec quality assurance directive professor kahn will assist in product development and product strategies of the company professor khan worked as a consultant for taurx therapeutics limited from  until the present he joined nemaura medical working for our wholly owned company dermal diagnostics limited in october of  and is the product development director david scott mr david scott is director of commercial development and licensing of the company he is a trained chemist with a bsc in chemistry from nottingham university in  he is a skilled negotiator who has closed a number of major deals for inward and outward licensing for pharmaceutical products delivery systems and technologies he has also provided licensing training for a number of multinational pharmaceutical companies and training organizations and has published numerous reports mr scott will assist the company in negotiating licensing contracts and development mr scott is an accredited certified licensing professional he joined nemaura medical working for our wholly owned company dermal diagnostics limited in september of  and is currently the director of commercial development and licensing richard toon dr richard toon is business and technical development manager of the company dr toon is a chartered chemist who originally trained as a synthetic chemist and more recently trained in law he received his bsc from nottingham university in  and his phd in organic chemistry from loughborough university in  more recently he received his graduate diploma law  from nottingham trent university when he focused his career has on commercial law activities such as contract negotiation intellectual property issues and business development dr toon was a research specialist at m healthcare from  to  then an enterprise business manager at keele university from  to  dr toon joined nemaura medical working for our wholly owned company dermal diagnostics limited in october of  and is our business and technical development manager bashir timol mr bashir timol is director of the company since december   he has been a director of dermal diagnostics limited from october   at nemaura mr timol is responsible for financial planning business and market development and corporate strategies mr timol possesses over  years experience in food and beverage franchise and logistic operations his experience includes constructing sales contracts and having the responsibility for overseeing the key managers in the operation of a large scale retail food chain he has experience as an entrepreneur investing in and operating a number of retail food chains in the uk including dixy chicken and costa coffee prior to joining nemaura mr timol has been employed as a director at sabt  ltd since march of  and onee group since january of  mr timol holds a bachelor degree in economics from the university of central lancashire uk timothy johnson mr timothy johnson serves as independent director of the company mr johnson is currently a director at diagnostax advisory a digital management consultancy and has built up a decade of insight and experience bringing new products and technologies to established markets he is a practicing chartered tax adviser and earned his first class masters of science in mathematics and physics from the university of manchester uk basic compensation name fiscal year total dewan chowdhury  iain anderson  karrar khan  david scott  richard toon  bashir timol  timothy johnson  as of   mar  options compensation name options value dewan chowdhury   iain anderson   karrar khan   david scott   richard toon   bashir timol   timothy johnson   insider trading » full list on insider trading related topics stocksstock screenermarket datahealthcaremedical equipment supplies  distribution nemaura medical inc announces uplist to otcqb  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street nemaura medical inc announces uplist to otcqb business wire jul    am edt nemaura medical inc otc nmrd a medical technology company focused on the development and commercialization of sugarbeat® a wireless disposable adhesive skinpatch for adjunctive use by diabetics as a noninvasive and needlefree continuous glucose monitoring cgm system announced it has recently uplisted to the otcqb venture market trading platform dr faz chowdhury ceo of nemaura medical commented we are pleased to announce our uplist to the otc quote board which we expect will enhance our visibility in the marketplace broaden and diversify our investor base and increase the liquidity of our common stock about nemaura medical inc nemaura medical is a medical technology company developing the wireless sugarbeat® disposable adhesive skinpatch as a noninvasive needlefree painfree and affordable continuous glucose monitoring cgm system for adjunctive use by diabetics for more information please visit  wwwnemauramedicalcom cautionary statement regarding forward looking statements the statements in this press release that are not historical facts and may constitute forwardlooking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements those risks and uncertainties include but are not limited to risks related to regulatory approvals and the success of nemaura medicals ongoing studies including the safety and efficacy of nemaura medicals sugarbeat® cgm system the failure of future development and preliminary marketing efforts nemaura medicals ability to secure additional commercial partnering arrangements risks and uncertainties relating to nemaura medical and its partners ability to develop market and sell sugarbeat® the availability of substantial additional equity or debt capital to support its research development and product commercialization activities and the success of its research development regulatory approval marketing and distribution plans and strategies including those plans and strategies related to sugarbeat® these and other risks and uncertainties are identified and described in more detail in nemaura medicals filings with the securities and exchange commission including without limitation its annual report on form k for the current year its quarterly reports on form q and its current reports on form k nemaura medical undertakes no obligation to publicly update or revise any forwardlooking statements advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers nemaura medical inc to present sugarbeat® poster at the advanced technologies and treatments for diabetes symposium attd in paris february th   business wire nemaura medical inc to present sugarbeat® poster at the advanced technologies and treatments for diabetes symposium attd in paris february th  february    am eastern standard time loughborough englandbusiness wirenemaura medical inc otc bbnmrd “nemaura” a medical device company developing a noninvasive needlefree painfree dailydisposable and cost effective wireless cgm continuous glucose monitoring patch known as sugarbeat® today announced that its multicentre open label clinical study has been selected for poster exhibit at the advanced technologies and treatments for diabetes attd conference in paris from the th to th february  the poster will illustrate sugarbeat®’s miniaturized wireless format as a discreet coin sized oval device less than mm in height and also showcase the sugarbeat® mobile phone application which is designed to display blood glucose readings at any point in time and provide summary ambulatory glucose profiles agp the company expects to launch sugarbeat® in europe this year through its european licensee and following two rounds of discussions with the fda nemaura has completed its clinical investigation plan cip for a pma application and expects to complete the studies for a pma submission by the end of the year sugarbeat® is expected to be cost competitive due to its noninvasive design and lowcost consumables these consist of a reusable electronic bodyworn device and daily disposable patches linked to a smart phone app nemaura medical ceo dr faz chowdhury said “our sugarbeat® technology is a more flexible way for anyone living with diabetes to monitor their glucose levels users can choose which days to wear the patch without having to endure long wear durations of up to  days” the th annual conference on technologies and treatments for diabetes will attract over  delegates from all over the globe the conference is attended by the world’s leading researchers clinical practitioners and industrycorporate professionals and provides a forum for lively exchange of ideas and research relating to technologies treatment and prevention of diabetes related illnesses about nemaura medical inc nemaura medical is developing the sugarbeat® system as a noninvasive needlefree painfree and costeffective wireless continuous glucose monitoring system cgm for use as an adjunct device for blood glucose monitoring further opportunity may exist for use of the device in intensive care hospital settings where continuous glucose monitoring is critical cautionary statement regarding forward looking statements the statements in this press release that are not historical facts and may constitute forwardlooking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements those risks and uncertainties include but are not limited to risks related to regulatory approvals and the success of nemaura’s ongoing studies including the safety and efficacy of nemaura’s sugarbeat® cgm system the failure of future development and preliminary marketing efforts nemaura’s ability to secure additional commercial partnering arrangements risks and uncertainties relating to nemaura and its partners’ ability to develop market and sell the sugarbeat® system the availability of substantial additional equity or debt capital to support its research development and product commercialization activities and the success of its research development regulatory approval marketing and distribution plans and strategies including those plans and strategies related to its sugarbeat® system these and other risks and uncertainties are identified and described in more detail in nemaura’s filings with the securities and exchange commission including without limitation its annual report on form k for the current year its quarterly reports on form q and its current reports on form k nemaura undertakes no obligation to publicly update or revise any forwardlooking statements contacts investors  mediabashir timolnemaura medical incbashirtimolnemauramedicalcom contacts investors  mediabashir timolnemaura medical incbashirtimolnemauramedicalcom search advanced news search advanced news search log in sign up technology nemaura medical   search investors  home technology sugarbeat® about us leadership news contact us the future of diagnostic technology replacing traditional invasive methods of diagnosis and healthcare observation procedures our beat™ technology will allow for remote continuous monitoring of chronic diseases and health conditions an intuitive patientfriendly daily disposable skinpatch applied while the user goes about their daily life it is expected to significantly reduce the current and future burden on healthcare services by greatly enhancing health and wellness or disease management how it works passing a mild nonperceptible electric current across the skin our patented beat™ technology draws a small amount of selected molecules such as glucose into a patch placed on the skin these molecules are drawn out of the interstitial fluid which naturally sits just below the top layer of skin via a sensor the patientfriendly patch measures the amount of that molecule present converting it into a meaningful concentration value for clinical diagnosis or preliminary guidance for selftreatment multiple applications easily extended to other molecules or analytes and medicinal drugs present in the interstitial fluid of the skin our beat™ technology has broad ranging potential clinical and nonclinical applications including – diabetes glucose monitoring – athletic performance monitoring lactate monitoring – intensive care glucose monitoring and oxygen depletion   our blood glucose monitoring product sugarbeat® is anticipated to launch in europe in  with at least one additional application expected to also commence clinical trials in  sugarbeat® suitable for type  type  and prediabetics sugarbeat® provides realtime monitoring for better health management  through its noninvasive affordable patented wearable technology find out more  stay informed  commentsthis field is for validation purposes and should be left unchanged get in touch  copyright   nemaura all rights reserved code of business conduct and ethics cookie  privacy policy nemaura medical inc signs letter of intent with shenzen cas health corp for potential jv and manufacture of their sugarbeat system skip to main content advertisement advertisement home topicscardiovascular diabetes home healthcare implantables medical diagnostics neurology oncology orthopedics pain management prosthetics regenerative medicine surgical wearables watchmdt live search socialfacebook twitter youtube guidescompanies products learn digital login register subscribe channelspdd ced ecn wdd ww advertisement diabetes nemaura medical inc signs letter of intent with shenzen cas health corp for potential jv and manufacture of their sugarbeat system fri   am comments by nemaura medical inc nemaura medical inc a medical device company developing a minimally invasive needlefree wireless cgm continuous glucose monitoring patch known as sugarbeat today announced that it has signed a letter of intent loi with a chinese corporation shenzen cas health corporation limited which is a partially owned subsidiary of the chinese academy of science the letter of intent covers three potential joint venture arrangements relating specifically to sugarbeat including a setting up a joint venture company to distribute in china b setting up a manufacturing facility in china and c obtaining cfda approval nemaura medical recognizes the size and importance of the chinese market as a result the company has prioritized obtaining cfda regulatory approvals as the next step in fulfilling a primary objective under the loi nemaura medical anticipates a sugarbeat product launch in europe in  where it has previously obtained ce approval in the us nemaura medical has had discussions with the fda and anticipates completing its clinical program and submitting a pma application around mid  sugarbeat differs from existing cgm’s given it comprises an adhesive dailydisposable skinpatch which does not require insertion of a needlelike sensor inside the skin sugarbeat also provides users with tremendous flexibility as to when and how often they choose to wear the patch both of these factors are expected to empower users in a way current cgm’s cannot about nemaura medical inc nemaura medical is developing the sugarbeat system as a minimallyinvasive needlefree wireless continuous glucose monitoring system for use as an adjunct device for blood glucose monitoring further opportunity may exist for use of the device in intensive care hospital settings where continuous glucose monitoring is critical cautionary statement regarding forward looking statements the statements in this press release that are not historical facts and may constitute forwardlooking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements those risks and uncertainties include but are not limited to risks related to regulatory approvals and the success of nemaura’s ongoing studies including the safety and efficacy of nemaura’s sugarbeat cgm system the failure of future development and preliminary marketing efforts nemaura’s ability to secure additional commercial partnering arrangements risks and uncertainties relating to nemaura and its partners’ ability to develop market and sell the sugarbeat system the availability of substantial additional equity or debt capital to support its research development and product commercialization activities and the success of its research development regulatory approval marketing and distribution plans and strategies including those plans and strategies related to its sugarbeat system these and other risks and uncertainties are identified and described in more detail in nemaura’s filings with the securities and exchange commission including without limitation its annual report on form k for the current year its quarterly reports on form q and its current reports on form k nemaura undertakes no obligation to publicly update or revise any forwardlooking statements related reads att warns investors off “minitender” offer seeking  million shares below market price att revises outlook takes  billion charge on directv’s venezuela assets verizon was looking for nearly a b discount on yahoo deal before it got m off us probes ecommerce giant alibabas accounting practices advertisement advertisement view the discussion thread advertisement connect with medical design technology facebook twitter youtube resources about us advertising info contact us contributor guidelines digital editions directory faqs privacy policy product announcement form subscriptions terms  conditions topics cardiovascular diabetes home healthcare implantables medical diagnostics neurology oncology orthopedics pain management prosthetics regenerative medicine surgical wearables advantage business media  copyright  advantage business media